Published in Antimicrob Agents Chemother on December 01, 2005
Efflux-mediated drug resistance in bacteria: an update. Drugs (2009) 3.18
Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des (2015) 1.08
In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother (2011) 0.90
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother (2006) 0.88
Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol. Antimicrob Agents Chemother (2007) 0.80
Intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (2006) 0.75
Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis. Antimicrob Agents Chemother (2006) 0.75
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Genetic systems in staphylococci. Methods Enzymol (1991) 9.00
Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol (1991) 3.70
Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother (1994) 3.57
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.12
Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother (1993) 3.10
Confirmation of protoplast fusion-derived linkages in Staphylococcus aureus by transformation with protoplast DNA. J Bacteriol (1983) 3.04
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother (1999) 2.75
Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureus. J Bacteriol (1994) 2.54
Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1989) 2.36
Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc Natl Acad Sci U S A (1998) 2.01
MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol (2005) 1.93
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol (2003) 1.81
Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother (1997) 1.71
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother (2000) 1.66
Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother (2005) 1.66
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.48
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother (2005) 1.35
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother (2002) 1.34
Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.30
Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.21
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Antimicrob Agents Chemother (2005) 1.15
Quinolone resistance due to reduced target enzyme expression. J Bacteriol (2003) 1.13
NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol (2002) 1.10
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.09
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother (2005) 1.03
Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob Agents Chemother (1998) 1.03
Mutants suppressing novobiocin hypersensitivity of a mukB null mutation. J Bacteriol (2003) 0.98
Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 0.98
Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001. Emerg Infect Dis (2004) 0.97
Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob Agents Chemother (2004) 0.81
The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis (2006) 7.20
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med (2005) 7.15
Hospital-acquired infections due to gram-negative bacteria. N Engl J Med (2010) 6.61
Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother (2003) 6.26
qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother (2006) 5.50
Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother (2006) 4.96
Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev (2009) 4.43
Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother (2005) 4.03
Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med (2008) 3.88
Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis (2013) 3.78
Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis (2006) 3.66
Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis (2013) 3.56
Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother (2004) 3.54
Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother (2005) 2.90
Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother (2008) 2.70
New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother (2009) 2.32
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Case records of the Massachusetts General Hospital. Case 3-2015. A 60-year-old woman with abdominal pain, dyspnea, and diplopia. N Engl J Med (2015) 1.97
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol (2003) 1.81
oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother (2009) 1.77
Discontinuation of contact precautions for methicillin-resistant staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. Clin Infect Dis (2013) 1.57
Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis (2004) 1.56
NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol (2008) 1.47
Recurrent meningitis of unknown aetiology. Lancet (2004) 1.43
A recA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus. J Biol Chem (2003) 1.41
NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.37
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother (2002) 1.34
Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.30
Mechanistic and structural analysis of aminoglycoside N-acetyltransferase AAC(6')-Ib and its bifunctional, fluoroquinolone-active AAC(6')-Ib-cr variant. Biochemistry (2008) 1.27
Detection of postoperative surgical-site infections: comparison of health plan-based surveillance with hospital-based programs. Infect Control Hosp Epidemiol (2003) 1.27
Citrobacter spp. as a source of qnrB Alleles. Antimicrob Agents Chemother (2011) 1.26
The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in Staphylococcus aureus. J Bacteriol (2007) 1.26
Transferable quinolone resistance in Vibrio cholerae. Antimicrob Agents Chemother (2009) 1.22
Temporal appearance of plasmid-mediated quinolone resistance genes. Antimicrob Agents Chemother (2009) 1.17
SOS regulation of qnrB expression. Antimicrob Agents Chemother (2008) 1.16
Enhanced surgical site infection surveillance following hysterectomy, vascular, and colorectal surgery. Infect Control Hosp Epidemiol (2012) 1.14
Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. J Biol Chem (2011) 1.13
Quinolone resistance due to reduced target enzyme expression. J Bacteriol (2003) 1.13
CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 28-2015. A 32-Year-Old Man with Fever, Headache, and Myalgias after Traveling from Liberia. N Engl J Med (2015) 1.13
Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated methicillin-resistant Staphylococcus aureus, 1997-2007. Clin Infect Dis (2012) 1.12
Epidemiology of dermatitis and skin infections in United States physicians' offices, 1993-2005. Clin Infect Dis (2009) 1.10
NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol (2002) 1.10
Use of Medicare diagnosis and procedure codes to improve detection of surgical site infections following hip arthroplasty, knee arthroplasty, and vascular surgery. Infect Control Hosp Epidemiol (2011) 1.09
Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother (2004) 1.08
Posttranslational modification influences the effects of MgrA on norA expression in Staphylococcus aureus. J Bacteriol (2008) 1.07
Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review. BMC Infect Dis (2014) 1.04
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother (2005) 1.03
Antibiotic dosing before primary hip and knee replacement as a pay-for-performance measure. J Bone Joint Surg Am (2007) 1.02
Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus. J Bacteriol (2010) 1.02
Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 0.98
Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance. Antimicrob Agents Chemother (2011) 0.97
Resource burden associated with contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: the patient access managers' perspective. Infect Control Hosp Epidemiol (2012) 0.94
Staphylococcus aureus NorD, a putative efflux pump coregulated with the Opp1 oligopeptide permease, contributes selectively to fitness in vivo. J Bacteriol (2012) 0.94
Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis (2014) 0.92
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob Agents Chemother (2002) 0.90
Phylogenetic analysis of chromosomally determined qnr and related proteins. Antimicrob Agents Chemother (2013) 0.90
Native efflux pumps contribute resistance to antimicrobials of skin and the ability of Staphylococcus aureus to colonize skin. J Infect Dis (2013) 0.89
Mutational analysis of quinolone resistance protein QnrB1. Antimicrob Agents Chemother (2013) 0.89
National survey of infection preventionists: policies for discontinuation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. Infect Control Hosp Epidemiol (2012) 0.88
Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother (2006) 0.88
An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr Purif (2005) 0.88
Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea. J Antimicrob Chemother (2013) 0.87
Reduced aeration affects the expression of the NorB efflux pump of Staphylococcus aureus by posttranslational modification of MgrA. J Bacteriol (2012) 0.87
Implication of the NorB efflux pump in the adaptation of Staphylococcus aureus to growth at acid pH and in resistance to moxifloxacin. Antimicrob Agents Chemother (2011) 0.85
Quinolone induction of qnrVS1 in Vibrio splendidus and plasmid-carried qnrS1 in Escherichia coli, a mechanism independent of the SOS system. Antimicrob Agents Chemother (2011) 0.83
Cold shock induces qnrA expression in Shewanella algae. Antimicrob Agents Chemother (2010) 0.82
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem (2005) 0.82
Induction of plasmid-carried qnrS1 in Escherichia coli by naturally occurring quinolones and quorum-sensing signal molecules. Antimicrob Agents Chemother (2013) 0.80
Risk factors and clinical characteristics of patients with qnr-positive Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother (2013) 0.79
Fungus-infected fluid collections in thorax or abdomen: effectiveness of percutaneous catheter drainage. Radiology (2005) 0.79
Regulation of expression of abcA and its response to environmental conditions. J Bacteriol (2014) 0.79
Concordance of PCR and culture from nasal swabs for detection of methicillin-resistant Staphylococcus aureus in a setting of concurrent antistaphylococcal antibiotics. J Clin Microbiol (2014) 0.76
Severe babesiosis in a patient treated with a tumor necrosis factor α antagonist. Clin Infect Dis (2012) 0.75